Fenofibrate PCD Pharma Franchise Company
Cafoli Lifecare offers a well-stocked Fenofibrate PCD pharma franchise built on 10 tablet formulations manufactured at WHO-GMP certified facilities. This gives franchise partners a core lipid-management line prescribed by cardiologists, diabetologists and physicians.
What is Fenofibrate?
Fenofibrate is a fibrate-class lipid-lowering agent that activates peroxisome proliferator-activated receptor alpha (PPAR-alpha). This markedly lowers triglycerides and raises HDL cholesterol, making it especially useful in mixed dyslipidaemia and hypertriglyceridaemia. Read its profile on MedlinePlus.
Therapeutic Applications
Fenofibrate is prescribed for severe hypertriglyceridaemia, mixed dyslipidaemia, and as an add-on to statins when triglycerides remain high or HDL is low. It is widely used in diabetic dyslipidaemia. Prescriptions come mainly from cardiologists, diabetologists, endocrinologists and general physicians.
Why Fenofibrate is a High-Potential Molecule for Distributors
India's high burden of diabetes and metabolic syndrome makes hypertriglyceridaemia extremely common, and fenofibrate is the go-to agent for it — frequently co-prescribed alongside statins. Lipid therapy is lifelong, generating continuous repeat sales, and the diabetic-dyslipidaemia overlap keeps the prescriber base wide. That makes fenofibrate a dependable, high-volume cardio-metabolic molecule for distributors.
Why Choose Cafoli Lifecare
Cafoli Lifecare provides territory-wise monopoly rights, WHO-GMP certified manufacturing, DCGI-approved formulations, complete promotional inputs and the backing of 1000+ franchise partners across India.
References
- MedlinePlus: Fenofibrate
- PubChem: Fenofibrate
Our formulations of Fenofibrate find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: